Predicting safety toleration of pharmaceutical chemical leads: Cytotoxicity correlations to exploratory toxicity studies

Toxicology Letters

Volumn 197, Issue 3, 2010, Pages 175-182

  Benbow, John W ^a   Aubrecht, Jiri ^a   Banker, Michael J ^a   Nettleton, David ^a   Aleo, Michael D ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Cytotoxicity; Drug discovery; Drug safety screening; Hazard assessment; In vitro screening; THLE cells

Indexed keywords

ALANINE AMINOTRANSFERASE; AURORA KINASE INHIBITOR; CHOLESTEROL; CHOLESTEROL ESTERASE TRANSFER PROTEIN INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUTAMATE RECEPTOR ANTAGONIST; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; HISTONE H3; PHOSPHODIESTERASE INHIBITOR; PROTEIN INHIBITOR; PROTEIN KINASE B INHIBITOR; SEROTONIN 2C ANTAGONIST; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ARTICLE; CELL VIABILITY; CHOLESTEROL BLOOD LEVEL; CONVULSION; DRUG CYTOTOXICITY; DRUG SAFETY; FOOD INTAKE; HAZARD ASSESSMENT; HISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; LC 50; LUNG EDEMA; MALE; NECROSIS; NONHUMAN; PRIORITY JOURNAL; RAT; RETICULOCYTE COUNT; RETROSPECTIVE STUDY; TOXICOKINETICS;

RATTUS;

EID: 77954954738     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2010.05.016     Document Type: Article

References (36)

1. Abraham V.C., Towne D.L., Waring J.F., Warrior U., Burns D.J. Application of a high-content multiparameter cytotoxicity assay to prioritize compounds based on toxicity potential in humans. J. Biomol. Screen. 2008, 13:527-537.
2. Aubrecht J., Osowski J.J., Persaud P., Cheung J.R., Ackerman J., Lopes S.H., Ku W.W. Bioluminescent Salmonella reverse mutation assay: a screen for detecting mutagenicity with high throughput attributes. Mutagenesis 2007, 22:335-342.
3. Barile F.A., Dierickx P.J., Kristen U. In vitro cytotoxicity testing for prediction of acute human toxicity. Cell Biol. Toxicol. 1994, 10:155-162.
4. Booth B., Zemmel R. Prospects for productivity. Nat. Rev. Drug Discov. 2004, 3:451-456.
5. Bugelski P.J., Atif U., Molton S., Toeg I., Lord P.G., Morgan D.G. A strategy for primary high throughput cytotoxicity screening in pharmaceutical toxicology. Pharm. Res. 2000, 17:1265-1272.
6. Cavero I., Kaplan H.R. Drug discovery paradigms: past, present, future - a centennial symposium of the American Society for Pharmacology and Experimental Therapeutics. Expert Opin. Drug Discov. 2008, 3:1145-1154.
7. Chackalamannil S., Desai M.C. Identifying quality leads - an important factor in reducing attrition of clinical candidates. Curr. Opin. Drug Discov. Dev. 2007, 10:381-382.
8. Clemedson C., Blaauboer B., Castell J., Prieto P., Risteli L., Vericat J.A., Wendel A. ACuteTox - optimation and pre-validation of an in vitro test strategy for predicting human acute toxicity. ALTEX 2006, 23(Suppl.):254-258.
9. Cochran W.G., Cox G.M. Experimental Designs 1959, John Wiley & Sons, New York.
10. Combes R., Barratt M., Balls M. An overall strategy for the testing of chemicals for human hazard and risk assessment under the EU REACH system. Altern. Lab. Anim. 2006, 34(Suppl. 1):15-27.
11. Dambach D.M., Andrews B.A., Moulin F. New technologies and screening strategies for hepatotoxicity: use of in vitro models. Toxicol. Pathol. 2005, 33:17-26.
12. DiMasi J.A., Hansen R.W., Grabowski H.G. The price of innovation: new estimates of drug development costs. J. Health Econ. 2003, 22:151-185.
13. Dunnett C.W. Multiple comparison procedure for comparing several treatments with a control. J. Am. Stat. Assoc. 1955, 50:1096-1121.
14. Dunnett C.W. New tables for multiple comparisons with a control. Biometrics 1964, 20:402-492.
15. Ekwall B., Ekwall B., Sjorstrom M. MEIC evaluation of acute systemic toxicity. Part VIII. Multivariate partial least squares evaluation, including the selection of a battery of cell line tests with a good prediction of human acute lethal peak blood concentrations for 50 chemicals. Altern. Lab. Anim. 2000, 28(Suppl. 1):201-234.
16. Evans S.M., Casartelli A., Herreros E., Minnick D.T., Day C., George E., Westmoreland C. Development of a high throughput in vitro toxicity screen predictive of high acute in vivo toxic potential. Toxicol. In Vitro 2001, 15:579-584.
17. Fielden M.R., Kolaja K.L. The role of early in vivo toxicity testing in drug discovery toxicology. Expert Opin. Drug Saf. 2008, 7:107-110.
18. Gerets H.H.J., Hanon E., Cornet M., Dhalluin S., Depelchin O., Canning M., Atienzar F.A. Selection of cytotoxicity markers for the screening of new chemical entities in a pharmaceutical context: a preliminary study using a multiplexing approach. Toxicol. In Vitro 2009, 23:319-332.
19. Gulden M., Seibert H. Impact of bioavailability on the correlation between in vitro cytotoxic and in vivo acute fish toxic concentrations of chemicals. Aquat. Toxicol. 2005, 72:327-337.
20. Houck K.A., Kavlock R.J. Understanding mechanisms of toxicity: Insights from drug discovery research. Toxicol. Appl. Pharmacol. 2008, 227:163-178.
21. Hughes J.D., Blagg J., Price D.A., Bailey S., Decrescenzo G.A., Devraj R.V., Ellsworth E., Fobian Y.M., Gibbs M.E., Gilles R.W., Greene N., Huang E., Krieger-Burke T., Loesel J., Wager T., Whiteley L., Zhang Y. Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg. Med. Chem. Lett. 2008, 18:4872-4875.
22. Kitagaki M., Wakuri S., Hirota M., Tanaka N., Itagaki H. Sirc-cvs cytotoxicity test: an alternative for predicting rodent acute systemic toxicity. J. Toxicol. Sci. 2006, 31:371-379.
23. Kola I., Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat. Rev. Drug Discov. 2004, 3:711-716.
24. Kramer J.A. Designing safe drugs: what to consider?. Expert Opin. Drug Discov. 2008, 3:707-713.
25. Kramer J.A., Sagartz J.E., Morris D.L. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nat. Rev. Drug Discov. 2007, 6:636-649.
26. Leeson P.D., Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discov. 2007, 6:881-890.
27. NICEATM-ICCVAM, November 2006. ICCVAM test method evaluation report (TMER): in vitro cytotoxicity test methods for estimating starting doses for acute oral systemic toxicity testing. NIH Publication No 07-4519. <> (accessed May 2010). http://iccvam.niehs.nih.gov/methods/acutetox/inv_nru_tmer.htm.
28. Noor F., Niklas J., Müller-Vieira U., Heinzle E. An integrated approach to improved toxicity prediction for the safety assessment during preclinical drug development using Hep G2 cells. Toxicol. Appl. Pharmacol. 2009, 237:221-231.
29. O'Brien P.J., Irwin W., Diaz D., Howard-Cofield E., Krejsa C.M., Slaughter M.R., Gao B., Kaludercic N., Angeline A., Bernardi P., Brain P., Hougham C. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch. Toxicol. 2006, 80:580-604.
30. Pfeifer A.M., Cole K.E., Smoot D.T., Weston A., Groopman J.D., Shields P.G., Vignaud J.M., Juillerat M., Lipsky M.M., Trump B.F., et al. Simian virus 40 large tumor antigen-immortalized normal human liver epithelial cells express hepatocyte characteristics and metabolize chemical carcinogens. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:5123-5127.
31. Pollard C.E., Valentin J.P., Hammond T.G. Strategies to reduce the risk of drug-induced QT interval prolongation: a pharmaceutical company perspective. Br. J. Pharmacol. 2008, 154:1538-1543.
32. Proudfoot J.R. Drugs, leads, and drug-likeness: an analysis of some recently launched drugs. Bioorg. Med. Chem. Lett. 2002, 12:1647-1650.
33. Reichert J.M. Trends in development and approval times for new therapeutics in the United States. Nat. Rev. Drug Discov. 2003, 2:695-702.
34. Sayes C.M., Marchione A.A., Reed K.L., Warheit D.B. Comparative pulmonary toxicity assessments of C60 water suspensions in rats: Few differences in fullerene toxicity in vivo in contrast to in vitro profiles. Nano Lett. 2007, 7:2399-2406.
35. Sokal R., Rohlf F.J. Biometry: The Principles and Practice of Statistics in Biological Research 1969, W. H. Freeman and Co., San Francisco, pp. 776.
36. Xu J.J., Diaz D., O'Brien P.J. Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential. Chem. Biol. Interact. 2004, 150:115-128.